Evolus Inc (EOLS) concluded trading on Thursday at a closing price of $9.27, with 0.42 million shares of worth about $3.93 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -14.88% during that period and on July 03, 2025 the price saw a gain of about 0.65%. Currently the company’s common shares owned by public are about 64.45M shares, out of which, 57.03M shares are available for trading.
Stock saw a price change of -0.43% in past 5 days and over the past one month there was a price change of -6.93%. Year-to-date (YTD), EOLS shares are showing a performance of -16.34% which decreased to -16.03% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.67 but also hit the highest price of $17.82 during that period. The average intraday trading volume for Evolus Inc shares is 1.10 million. The stock is currently trading -2.87% below its 20-day simple moving average (SMA20), while that difference is down -8.15% for SMA50 and it goes to -26.59% lower than SMA200.
Evolus Inc (NASDAQ: EOLS) currently have 64.45M outstanding shares and institutions hold larger chunk of about 84.38% of that.
The stock has a current market capitalization of $597.69M and its 3Y-monthly beta is at 1.13. It has posted earnings per share of -$0.89 in the same period. It has Quick Ratio of 2.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EOLS, volatility over the week remained 3.79% while standing at 4.31% over the month.
Analysts are in expectations that Evolus Inc (EOLS) stock would likely to be making an EPS of -0.09 in the current quarter, while forecast for next quarter EPS is -0.06 and it is 0.59 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.11 which is -0.05 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.06 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 23.26% while it is estimated to increase by 393.56% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on April 17, 2025 offering a Buy rating for the stock and assigned a target price of $21 to it. Coverage by Barclays stated Evolus Inc (EOLS) stock as an Overweight in their note to investors on January 29, 2024, suggesting a price target of $16 for the stock. On June 23, 2022, Needham Initiated their recommendations, while on May 12, 2022, Barclays Upgrade their ratings for the stock with a price target of $10. Stock get a Buy rating from Truist on January 20, 2022.
